Arthritis News and Research

Latest Arthritis News and Research

Ten physicians indicted in alleged $250 million fraud scheme

As has been the trend in some recent health care fraud cases, the physicians were not the ringmasters. Instead, the indictments allege that they were fronts for others - primarily immigrants from the former Soviet Union.

2 Mar 2012

Akeso Medical Imaging starts clinical study for proof of concept of imaging device for rheumatoid arthritis disease activity monitoring and control

Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso’s imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.

1 Mar 2012

Cyclotides discovery may open up new possibilities for immune suppression

A team of researchers at the MedUni Vienna, together with scientists from the University Hospital of Freiburg, has decoded a mechanism in cyclic plant peptides, known as cyclotides, from the family of coffee plants (Rubiaceae) that could open up new possibilities for immune suppression.

1 Mar 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

TUT creates first biodegradable joint implant for arthritic patients

Tampere University of Technology (TUT), Finland, has been the first in the world to develop biodegradable joint implant, RegJoint-. The implant is used in the treatment of osteoarthritis and rheumatoid arthritis.

29 Feb 2012

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

Qnexa took a step closer to approval on Wednesday, when outside advisers to the U.S. Food and Drug Administration voted 20-to-2 in favor of approval. The panel also recommended the company conduct a study to scrutinize even more closely any risk of heart problems. That study may be required after the drug is approved. Should the FDA ask for further data on heart risks before any approval, it would delay Qnexa's launch further.

26 Feb 2012

Blue Belt's Navio PFS System receives CE Mark approval

Blue Belt Technologies, Inc., a medical device company focused on developing the next generation of "smart" surgical instruments providing precise robotic control for use initially in orthopedic procedures and then for other surgical specialties including neurosurgery, spinal and otolaryngology, announced today that it has received CE Mark for the Navio™ PFS System.

24 Feb 2012

Scientists identify specific mechanisms by which vitamin D inhibits inflammation

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling.

24 Feb 2012

NHS approves new rheumatoid arthritis drug RoActemra

RoActemra, which is the first innovation in the field for ten years, is being recommended for patients who have failed on standard treatments. It is the first time RoActemra has been approved for NHS patients in England and Wales with moderate to severe rheumatoid arthritis who are at an early stage in the disease. The drug has been available for early use in Scotland for two years.

23 Feb 2012

NK cells play an important role in rejection of porcine chondrocytes transplantation

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have studied for the first time the response of human NK cells (Natural Killer) against porcine chondrocytes (cartilage cells).

23 Feb 2012

Mount Sinai receives Le Foundation gift for psychiatric neuroimaging study

The Department of Psychiatry at Mount Sinai School of Medicine has received a $250,000 gift from The Iris & Junming Le Foundation to advance neuroimaging research conducted by young scientists in the early stages of their careers.

23 Feb 2012

Questcor fourth quarter net sales increase to $75.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2011.

22 Feb 2012

State roundup: Calif. expands uninsured access, gives adult day care reprieve

Nearly two years before the federal health reform law kicks in, 10 California counties have expanded medical coverage to more than 250,000 people who were previously uninsured, according to new state data.

22 Feb 2012

Medco fourth-quarter total net revenues increase 12.2% to record $19.0 billion

Medco Health Solutions, Inc. today reported record fourth-quarter 2011 GAAP diluted EPS of $1.08, an increase of 22.7 percent, which includes expenses associated with the pending merger with Express Scripts, Inc. of $43.6 million before provision for income taxes. When excluding these merger-related expenses, diluted EPS increased 29.5 percent over fourth-quarter 2010.

21 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

Scientists discover the off signal for inflammation

Proteins, the building block for all living organisms, are the ultimate transformers - able to splice and switch roles and functions within the human body. But when these changes go wrong, diseases such as cancers and arthritis may result, says University of British Columbia researcher Chris Overall.

18 Feb 2012

Abcodia, Volition announce collaboration agreement

VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces a collaboration agreement with Abcodia, a specialist company spun out from University College London (UCL), under which Volition will gain access to Abcodia's biobank of over 5,000,000 human serum samples to validate its suite of NuQ tests.

17 Feb 2012

Pharmos reports net loss of $0.4 million for fourth quarter 2011

Pharmos Corporation reported financial results for the fourth quarter and twelve-month period ended December 31, 2011. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC.

17 Feb 2012

Web-based intervention can effectively manage chronic migraine

painACTION.com is a free, non-promotional online program designed to support self-management and improve overall function in people with chronic pain. This study tested painACTION.com's ability to increase the use of self-management skills in people with chronic migraine headaches.

17 Feb 2012